| DHR |
Report |
Adjusted EPS (Q2 2026) |
BEAT |
pred ~$1.90 vs. cons $1.84 |
MEDIUM |
| DHR |
Report |
Biotechnology/bioprocessing core growth & equipment orders (Q2) |
BEAT |
pred ~+7% core, equipment orders +20-30% y/y vs. cons ~+6% / +MSD |
MEDIUM |
| DHR |
Report |
Core (organic) revenue growth (Q2 2026) |
IN-LINE |
pred ~2.5% vs. cons ~2% |
MEDIUM |
| DHR |
Guide |
FY2026 adjusted EPS guidance |
BETTER |
guide ~$8.45-8.60 (mid ~$8.53) vs. cons ~$8.50 (FY2026) |
MEDIUM |
| DHR |
Guide |
FY2026 core revenue growth range |
UNCHANGED |
guide 3%-6% (anchored low end ~3.5%) vs. cons ~3.5% (FY2026) |
HIGH |
| DHR |
Guide |
Exit-Q4 / 2H mid-single-digit core acceleration credibility |
UNKNOWN |
guide exit-Q4 ~+MSD (~5%) vs. cons ~4-5% (2H/Q4 2026) |
LOW |
| DHR |
Guide |
Q3 2026 core growth guide |
UNCHANGED |
guide ~+low-to-mid single digits (~3%) vs. cons ~3% (Q3 2026) |
LOW |
| DHR |
Guide |
Masimo deal timing/financing & interest expense |
UNKNOWN |
guide close later-2026, net debt ~2.5x EBITDA vs. cons excludes deal (FY2026) |
LOW |
| DHR |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
MEDIUM |
| DHR |
Return |
5-day cumulative residual |
+1.0% (FADE) |
Expect a clean Q2 beat (DHR's typical pattern) plus a modest EPS guide bump and a second quarter of >20-30% bioprocessing equipment orders to drive an initial +2-3% idiosyncratic pop. But the stock has already rallied ~15% off May lows into the print on improved lab-tool sentiment (Agilent/ICON/Bio-Techne), so much of the good news is priced. The 2H re-acceleration remains a 'show-me' math story (headwinds fading rather than end-markets improving), so out-period FY/2027 estimates barely rise even after the beat; skepticism on the exit-Q4 mid-single-digit ramp plus Masimo capital-deployment overhang causes the pop to partially give back over the week. |
LOW |